The effect of CYP3A4 inhibitors on DAT imaging using 123I-FP-CIT
| dc.rights.license | CC-BY-NC-ND | |
| dc.contributor.advisor | Garde, E.M.W. van de | |
| dc.contributor.author | Yağci, Eda | |
| dc.date.accessioned | 2024-11-01T01:01:55Z | |
| dc.date.available | 2024-11-01T01:01:55Z | |
| dc.date.issued | 2024 | |
| dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/48067 | |
| dc.description.sponsorship | Utrecht University | |
| dc.language.iso | EN | |
| dc.subject | DAT SPECT imaging with [123I]I-FP-CIT can be used for the diagnosis of PD and DLB. [123I]I-FP-CIT undergoes some metabolic changes in the body. One of the metabolic pathways occurs through CYP3A4, leading to the formation of [123I]I-nor-β-CIT, which crosses the blood-brain barrier. There are medications that inhibit CYP3A4 enzymes, which could potentially affect the metabolism of [123I]I-FP-CIT. Our hypothesis is that the inhibition of CYP3A4 will lead to a more reliable diagnosis of PD and DLB. | |
| dc.title | The effect of CYP3A4 inhibitors on DAT imaging using 123I-FP-CIT | |
| dc.type.content | Master Thesis | |
| dc.rights.accessrights | Open Access | |
| dc.subject.courseuu | Farmacie | |
| dc.thesis.id | 26440 |
